SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Sunesis Pharmaceuticals, Inc.

395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650-266-3500
http://www.sunesis.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees29

Key Executives

NameTitlePayExercisedYear Born
Mr. Dayton MisfeldtInterim CEO & Director50kN/A1974
Mr. William P. QuinnSr. VP of Fin. & Corp. Devel. and CFO449.63kN/A1971
Dr. Judith A. FoxChief Scientific Officer and Exec. VP of R&DN/AN/AN/A
Mr. Stephen NavaVP of Quality Assurance, Compliance & Regulatory AffairsN/AN/AN/A
Dr. Deborah A. ThomasSr. VP, Regulatory Affairs, Quality Assurance & PharmacovigilanceN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

Sunesis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.